Programmed cell death ligand-1 expression in gastroenteropancreatic neuroendocrine tumors

Simple item page
dc.contributor.authorOktay E.
dc.contributor.authorYalcin G.D.
dc.contributor.authorEkmekci S.
dc.contributor.authorKahraman D.S.
dc.contributor.authorYalcin A.
dc.contributor.authorDegirmenci M.
dc.contributor.authorDirican A.
dc.contributor.authorAltin Z.
dc.contributor.authorOzdemir O.
dc.contributor.authorSurmeli Z.
dc.contributor.authorDiniz G.
dc.contributor.authorAyhan S.
dc.contributor.authorBulut G.
dc.contributor.authorErdogan A.
dc.contributor.authorUslu R.
dc.date.accessioned2024-07-22T08:08:45Z
dc.date.available2024-07-22T08:08:45Z
dc.date.issued2019
dc.description.abstractPurpose: Gastroenteropancreatic tumors (GEPNETs) is a heterogeneous disease with variable clinical course. While promising therapeutic options exist for other adult cancers, there are no new molecular-based treatments developed for GEPNETs. One of the main targets of cancer immunotherapy is the Programmed Cell Death Ligand-1 (PD-L1) pathway. Our purpose was to investigate the profile of PD-L1 expression in different organs of GEPNETs and compare the conventional immunohistochemistry (IHC) with the RNA expression analysis via real time polymerase chain reaction (RT-PCR) in order to determine which patients might be appropriate for immune check point-targeted therapy. Methods: A total of 59 surgically or endoscopically resected GEPNET tissues were retrospectively collected. The expression of PD-L1 and mRNA was evaluated with IHC. Results: The expression of PD-L1 was significantly associated with the high-grade classification (p=0.012). PD-L1 mRNA expression in tumor samples appeared to be higher compared to the corresponding normal tissues. In appendix, stomach and small intestine, the expression of PD-L1 mRNA was higher in the tumor tissues compared to the respective controls. In pancreas and colon, control tissues tend to have a higher PD-L1 mRNA expression compared to tumor tissues. PD-L1 mRNA expression was higher in GEP carcinomas (p=0.0031). Conclusion: RT-PCR was found to be more sensitive in detecting PD-L1 expression than conventional IHC. This study may provide an important starting point and useful background information for future research about immunotherapy for appendix, stomach and small intestine neuroendocrine carcinomas. © 2019 Zerbinis Publications. All rights reserved.
dc.identifier.issn11070625
dc.identifier.urihttp://akademikarsiv.cbu.edu.tr:4000/handle/123456789/14522
dc.language.isoEnglish
dc.publisherZerbinis Publications
dc.subjectAdolescent
dc.subjectAdult
dc.subjectAged
dc.subjectAged, 80 and over
dc.subjectApoptosis
dc.subjectB7-H1 Antigen
dc.subjectCarcinoma, Neuroendocrine
dc.subjectColon
dc.subjectFemale
dc.subjectGastric Mucosa
dc.subjectGene Expression Regulation, Neoplastic
dc.subjectHumans
dc.subjectImmunohistochemistry
dc.subjectImmunotherapy
dc.subjectIntestinal Neoplasms
dc.subjectIntestine, Small
dc.subjectMale
dc.subjectMiddle Aged
dc.subjectNeuroendocrine Tumors
dc.subjectPancreas
dc.subjectPancreatic Neoplasms
dc.subjectRNA, Messenger
dc.subjectStomach Neoplasms
dc.subjectYoung Adult
dc.subjectactin
dc.subjectcomplementary DNA
dc.subjectmessenger RNA
dc.subjectprogrammed death 1 ligand 1
dc.subjectRNA
dc.subjectCD274 protein, human
dc.subjectmessenger RNA
dc.subjectprogrammed death 1 ligand 1
dc.subjectadult
dc.subjectaged
dc.subjectappendix cancer
dc.subjectArticle
dc.subjectclinical classification
dc.subjectclinical evaluation
dc.subjectcolon cancer
dc.subjectcomparative study
dc.subjectcontrolled study
dc.subjectdisease association
dc.subjectfemale
dc.subjectgastroenteropancreatic neuroendocrine tumor
dc.subjectgenetic association
dc.subjecthuman
dc.subjecthuman tissue
dc.subjectimmunohistochemistry
dc.subjectmajor clinical study
dc.subjectmale
dc.subjectmolecularly targeted therapy
dc.subjectmRNA expression assay
dc.subjectneuroendocrine carcinoma
dc.subjectpancreas cancer
dc.subjectprotein expression
dc.subjectreal time polymerase chain reaction
dc.subjectretrospective study
dc.subjectsmall intestine cancer
dc.subjectstomach cancer
dc.subjectvery elderly
dc.subjectadolescent
dc.subjectapoptosis
dc.subjectcarcinoma
dc.subjectcolon
dc.subjectgene expression regulation
dc.subjectgenetics
dc.subjectimmunohistochemistry
dc.subjectimmunology
dc.subjectimmunotherapy
dc.subjectintestine tumor
dc.subjectmetabolism
dc.subjectmiddle aged
dc.subjectneuroendocrine tumor
dc.subjectpancreas
dc.subjectpancreas tumor
dc.subjectpathology
dc.subjectsmall intestine
dc.subjectstomach mucosa
dc.subjectstomach tumor
dc.subjectyoung adult
dc.titleProgrammed cell death ligand-1 expression in gastroenteropancreatic neuroendocrine tumors
dc.typeArticle

Files

Collections

Scopus Koleksiyonu